Sign in
Taking people in United StatesPhase 2

Testing 2-hydroxybenzylamine for Salt-Sensitive High Blood Pressure

Tests 2-hydroxybenzylamine against placebo in adults whose blood pressure reacts to salt.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
30 Oct 2026
Expected to end
31 Jul 2031
Type of study
Interventional, 2 groups
Treatments tested
  • 2-hydroxybenzylamine
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults over 18 who were already tested and found to be salt-sensitive, meaning their blood pressure changes with salt intake. It tests the drug 2-hydroxybenzylamine against placebo.

Age
Over 18 years
Sex
All sexes
Disease stage
Salt sensitivity of blood pressure, defined as a rise in systolic blood pressure of 10 mmHg or more from salt-depletion to salt-loading. Resistant hypertension and office blood pressure above 160 mmHg systolic or 100 mmHg diastolic are excluded.
Earlier treatment
Cannot have used aspirin, MAO inhibitors, nitrate therapy, glucocorticoids, immunosuppressants, or drugs that raise blood pressure. Recent vaccination is not allowed.
Biomarker or test result
Previously tested as salt-sensitive (systolic blood pressure change of 10 mmHg or more).

Main reasons for not taking part

  • Salt-resistant people
  • Diabetes (type 1 or 2)
  • Autoimmune disease or active infection, including HIV/AIDS
  • Heart attack or other acute cardiovascular event in the past 6 months
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,
  • Over 18 years of age. Able to give informed consent,

Who cannot take part

  • Acute cardiovascular event(s) within the previous 6 months,
  • Current excessive alcohol or illicit drug use,
  • BP below the inclusion criteria levels after discontinuation of therapy,
  • Concomitant diabetes mellitus, type I or II,
  • Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,
  • Use of glucocorticoids, immunosuppressants, direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,
  • Use of monoamine oxidase inhibitors (MAO-I),
  • Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),
  • Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,
  • Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants/antipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction
  • Autoimmune disease,
  • Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,
  • Active or ongoing infection, including HIV/AIDS,
  • Active or ongoing malignancy with the exception of basal cell carcinoma of the skin,
  • Severe psychiatric disorders,
  • Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,
  • Individuals who have contraindications to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),
  • Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT >1.5x the upper limit of normal or total bilirubin ≥1.5 mg/dl,
  • Younger or older than inclusion criteria,
  • Salt-resistant people,
  • inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol,
  • Recent vaccination,
  • Pregnant or breastfeeding
  • Women of childbearing potential unwilling to use highly effective contraceptive (see Risk section),
  • Use of Aspirin,
  • Individuals with medical contraindications to certain food content,
  • Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A.Taking people

About the trial

What the trial wants to find out

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+).

Read full original descriptionShow less

This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.

This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

The 2 groups in the trial

  • Arm 1: Drug-washout-placeboTreatment being tested

    Participants with salt sensitivity of blood pressure to receive treatment with 2-HOBA (500mg) three times a day for 4 weeks, followed by a washout period of 4 weeks, and then placebo for 4 weeks

    Treatment: 2-hydroxybenzylamine and Placebo

  • Arm 2: Placebo-washout-DrugTreatment being tested

    Participants with salt sensitivity of blood pressure to receive treatment with placebo for 4 weeks followed by a washout period of 4 weeks, and then 2-HOBA (500mg) three times a day for 4 weeks.

    Treatment: 2-hydroxybenzylamine and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
Plain-language title
Testing 2-hydroxybenzylamine for Salt-Sensitive High Blood PressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026